natgillin/translations-raw huggingface dataset:
Renal changes including tubular degeneration, chronic inflammation and proteinurea were noted in rats and are felt to be attributable to species-specific spontaneous disease.
Pri podganah ugotovljene ledvične spremembe, Vključno z degeneracijo tubulov, kroničnim vnetjem in proteinurijo, veljajo za posledico spontane bolezni, specifične za to živalsko vrsto.
Pack sizes: 30, 90, 100 and multipack containing 90 (3 bottles of 30) film-coated tablets.
Velikosti pakiranja: 30 , 90, 100 in skupno pakiranje po 90 (3 plastenke po 30) filmsko obloženih tablet.
Muscle pain, tenderness or weakness, particularly in combination with antiretroviral therapy including protease inhibitors and nucleoside analogues.
bolečine v mišicah, občutljivost ali šibkost mišic, zlasti v kombinaciji z protiretrovirusnim zdravljenjem, vključno z zaviralci proteaz in nukleozidnimi analogi.
If Ritonavir Mylan is taken in combination with other antiretroviral medicines, it is important that you also carefully read the leaflets that are provided with these other medicines.
Če jemljete zdravilo Ritonavir Mylan v kombinaciji z drugimi protiretrovirusnimi zdravili, morate natančno prebrati tudi navodila, priložena tem drugim zdravilom.
Patients who exhibit these signs or symptoms should be evaluated and ritonavir therapy should be discontinued if a diagnosis of pancreatitis is made (see section 4.8).
Bolnike s temi znaki oz. simptomi je treba pregledati; če je diagnoza pankreatitisa potrjena, je treba zdravljenje z ritonavirjem prekiniti (glejte poglavje 4.8).
Phenytoin may decrease serum levels of ritonavir.
Fenitoin lahko zniža koncentracije ritonavirja v serumu.
Ritonavir is not a cure for HIV infection or AIDS.
Ritonavir ne ozdravi okužbe s HIV ali AIDS-a.
The recommended dose of ritonavir is 600 mg (6 tablets) twice daily (total of 1,200 mg per day) by mouth.
Odrasli Priporočen odmerek ritonavirja je 600 mg (6 tablet) peroralno dvakrat na dan (skupno 1200 mg na dan).
You must not take ritonavir with colchicine if you have kidney and/or liver problems (see also ‘Do not take Ritonavir Mylan' above).
Ritonavirja ne smete uporabljati hkrati s kolhicinom, če imate težave z ledvicami ali jetri (glejte tudi ‘Ne jemljite zdravila Ritonavir Mylan' zgoraj).
The following adverse reactions of moderate to severe intensity with possible or probable relationship to ritonavir have been reported.
Opisani so bili naslednji zmerni do hudi neželeni učinki, ki so morda ali verjetno povezani z ritonavirjem.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Bolnike s kroničnim hepatitisom B ali C, ki dobivajo kombinirano protiretrovirusno terapijo, bolj ogrožajo hudi in potencialno smrtni neželeni učinki na jetrih.
Concomitant use of ritonavir (400 mg twice daily and more) and voriconazole is contraindicated due to a reduction in voriconazole plasma concentrations and possible loss of effect (see section 4.5).
Sočasna uporaba ritonavirja (400 mg dvakrat na dan ali več) in vorikonazola je kontraindicirana zaradi znižanja koncentracije vorikonazola v plazmi in možne izgube učinka (glejte poglavje 4.5).
Potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment (see sections 4.4 and 4.5).
Možnost resnih in/ali življenjsko ogrožujočih neželenih učinkov pri bolnikih z okvaro ledvic in/ali jeter (glejte poglavji 4.4 in 4.5).
Each film-coated tablet contains 100 mg ritonavir.
Vsaka filmsko obložena tableta vsebuje 100 mg ritonavirja.
Due to the risk of QTc prolongation associated with DM-6705, if co-administration of delamanid with ritonavir is considered necessary, very frequent ECG monitoring throughout the full delamanid treatment period is recommended (see section 4.4 and refer to the delamanid Summary of Product Characteristics)
Zaradi tveganja za podaljšanje intervala QTc zaradi DM-6705, ko je bilo potrebno sočasno dajanje delamanida z ritonavirjem, se skozi celotno obdobje zdravljenja z delamanidom priporoča zelo pogosto spremljanje z EKG-jem (glejte poglavje 4.4 in poglejte povzetek glavnih značilnosti zdravila za delamanid).
Concurrent administration of bupropion with repeated doses of ritonavir is expected to decrease bupropion levels.
Pričakovati je, da sočasna uporaba bupropiona s ponavljajočimi odmerki ritonavirja zmanjša raven bupropiona.
Co-administration of delamanid with a strong inhibitor of CYP3A (ritonavir) may increase exposure to delamanid metabolite, which has been associated with QTc prolongation.
Sočasna uporaba delamanida z močnim zaviralcem CYP3A (ritonavirjem) lahko poveča izpostavljenost presnovku delamanida, ki ga povezujejo s podaljšanjem intervala QTc.
Serious persistent vomiting and/or diarrhoea associated with ritonavir use might also compromise renal function.
Hudo, dolgotrajno, z ritonavirjem povezano bruhanje in/ali driska lahko poleg tega ogrozi delovanje ledvic.
Because ritonavir is highly protein bound it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis.
Ker je ritonavir v veliki meri vezan na beljakovine, ni verjetno, da bi ga hemodializa ali peritonealna dializa odstranila v pomembni meri.
In addition to the interactions listed above, as ritonavir is highly protein bound, the possibility of increased therapeutic and toxic effects due to protein binding displacement of concomitant medicinal products should be considered.
Zato je poleg zgoraj naštetih interakcij treba upoštevati možnost večjih terapevtskih in toksičnih učinkov zaradi izpodrinjenja sočasno uporabljenih zdravil z vezave na beljakovine.
Since increased concentrations of lovastatin and simvastatin may predispose patients to myopathies, including rhabdomyolysis, the combination of these medicinal products with ritonavir is contraindicated (see section 4.3).
Ker lahko zvišana koncentracija lovastatina in simvastatina povzroči nagnjenost k miopatijam, vključno z rabdomiolizo, je sočasna uporaba teh zdravil z ritonavirjem kontraindicirana (glejte poglavje 4.3).
Modest prolongation of the PR interval was also noted in subjects receiving ritonavir in the same study on Day 3.
Med preiskovanci, ki so dobivali ritonavir, so v isti študiji 3. dan ugotovili zmerno podaljšanje intervala PR.
100 mg twice daily1
100 mg dvakrat na dan1
Proton pump inhibitors and H2-receptor antagonists Proton pump inhibitors and H2-receptor antagonists (e.g. omeprazole or ranitidine) may reduce concentrations for co-administered protease inhibitors.
Zaviralci protonske črpalke in antagonisti receptorjev H2: zaviralci protonske črpalke in antagonisti receptorjev H2 (npr. omeprazol ali ranitidin) lahko zmanjšajo koncentracijo sočasno uporabljenih zaviralcev proteaz.
Ritonavir may induce glucuronidation and oxidation by CYP1A2, CYP2C8, CYP2C9 and CYP2C19 thereby increasing the biotransformation of some medicinal products metabolised by these pathways, and may result in decreased systemic exposure to such medicinal products, which could decease or shorten their therapeutic effect.
Ritonavir lahko inducira glukuronidacijo in oksidacijo s CYP1A2, CYP2C8, CYP2C9 in CYP2C19 in tako lahko poveča biotransformacijo nekaterih zdravil, ki se presnavljajo po teh poteh.
Tell your doctor if you experience:
Zdravniku morate povedati, če se vam pojavi/pojavijo:
The increased digoxin levels may lessen over time (see section 4.5).
Zvišanje koncentracije digoksina se lahko sčasoma zmanjša (glejte poglavje 4.5).
Therefore, ritonavir should not be co-administered with orally administered midazolam (see section 4.3), whereas caution should be used with co-administration of ritonavir and parenteral midazolam.
Zato ritonavirja ne smete uporabljati sočasno s peroralnim midazolamom (glejte poglavje 4.3), v primeru sočasne uporabe ritonavirja in parenteralnega midazolama pa je potrebna previdnost.
(For caution on parenterally administered midazolam, see section 4.5.
(Za previdnost pri uporabi parenteralnega midazolama glejte poglavje 4.5.)
Co-administration of ritonavir with these medicinal products is expected to substantially increase their concentrations and may result in associated adverse reactions such as hypotension and prolonged erection (see section 4.5).
Pričakovati je treba, da sočasna uporaba ritonavirja in teh zdravil bistveno zviša njihovo koncentracijo in lahko povzroči z njimi povezane neželene učinke, npr. hipotenzijo in dolgotrajno erekcijo (glejte poglavje 4.5).
Hypertension, hypotension including orthostatic hypotension, peripheral coldness
Hipertenzija, hipotenzija vključno z otrostatsko hipotenzijo, hladne okončine
Medicinal product interactions - Ritonavir with protease inhibitors
Medsebojno delovanje zdravil - ritonavir z zaviralci proteaz
INFORMATION IN BRAILLE Ritonavir Mylan
PODATKI V BRAILLOVI PISAVI Ritonavir Mylan
Ritonavir was not found to be mutagenic or clastogenic in a battery of in vitro and in vivo assays including the Ames bacterial reverse mutation assay using S. typhimurium and E. coli, the mouse lymphoma assay, the mouse micronucleus test and chromosomal aberration assays in human lymphocytes.
Mutagenost ritonavirja so preizkusili s skupino preskusov in vitro in in vivo, med drugim z Amesovim preskusom bakterijske reverzne mutacije (z uporabo S. typhimurium in E. coli), mišjim limfomskim preskusom, mikronukleusnim testom pri miših in preskusi kromosomskih aberacij v človeških limfocitih.
Animal data have shown reproductive toxicity (see section 5.3).
Podatki pri živalih so pokazali toksične učinke na sposobnost razmnoževanja (glejte poglavje 5.3).
Ritonavir has selective affinity for the HIV protease and has little inhibitory activity against human aspartyl proteases.
Ritonavir ima selektivno afiniteto za HIV-proteaze in le malo zavira človeške aspartilproteaze.
HDPE bottle with polypropylene screw cap with inbuilt desiccant.
Steklenica iz HDPE s polipropilenskim navojnim pokrovčkom, ki ima vgrajeno sušilno sredstvo.
Increased plasma concentrations of astemizole and terfenadine.
Zvišana koncentracija astemizola in terfenadina v plazmi.
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John's wort (see section 4.3).
Indukcijski učinek lahko traja še vsaj 2 tedna po opustitvi šentjanževke (glejte poglavje 4.3).
If you take more Ritonavir Mylan than you should
Če ste vzeli večji odmerek zdravila Ritonavir Mylan, kot bi smeli
Consequently, concomitant administration of ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4).
Zato sočasna uporaba ritonavirja, odmerjanega kot protiretrovirusno zdravilo ali kot farmakokinetični stopnjevalec, in teh glukokortikoidov ni priporočljiva, razen če možna korist terapije odtehta tveganja sistemskih učinkov kortikosteroidov (glejte poglavje 4.4).
Doses of ritonavir lower than 200 mg twice daily should not be used as they might alter the efficacy profile of the combination.
Odmerkov ritonavirja, manjših od 200 mg dvakrat na dan, ne smete uporabljati, ker lahko spremenijo učinkovitost kombinacije.
The metabolism of pravastatin and fluvastatin is not dependent of CYP3A, and interactions are not expected with ritonavir.
Presnova pravastatina in fluvastatina ni odvisna od CYP3A in medsebojnega delovanja z ritonavirjem ni pričakovati.
What you need to know before you or your child takes Ritonavir Mylan
Kaj morate vedeti, preden boste vi ali vaš otrok vzeli zdravilo Ritonavir Mylan
Co-administration of bosentan and ritonavir may increase steady state bosentan maximum concentrations (Cmax) and area under the curve (AUC).
Sočasna uporaba bosentana in ritonavirja lahko poveča maksimalno koncentracijo bosentana v stanju dinamičnega ravnovesja in površino pod krivuljo (AUC).
Serum concentrations may be increased due to CYP3A inhibition by ritonavir, resulting in increased risk of tumour lysis syndrome at the dose initiation and during the ramp-up phase (see section 4.3 and refer to the venetoclax SmPC).
Serumske koncentracije se lahko povečajo zaradi zavrtja CYP3A z ritonavirjem, posledično se poveča tveganje za pojav sindroma tumorske lize pri začetnem odmerjanju in med fazo povečevanja odmerka (glejte poglavje 4.3 in povzetek glavnih značilnosti zdravila za venetoklaks).
Furthermore, no clinically significant renal abnormalities were noted in clinical trials.
Poleg tega med kliničnimi preskušanji niso ugotovili nobenih klinično pomembnih ledvičnih nepravilnosti.
Ritonavir Mylan tablets should be taken with food.
Filmsko obložene tablete Ritonavir Mylan vzemite s hrano.
Haemophilia, as there have been reports of increased bleeding in patients with haemophilia who are taking this type of medicine (protease inhibitors).
hemofilijo, opisani so primeri večjih krvavitev pri bolnikih, ki so jemali to vrsto zdravil (zaviralce proteaz).
Increased digoxin levels observed in patients receiving ritonavir may lessen over time as induction develops (see section 4.4).
Zvišana koncentracija digoksina, ugotovljena pri prejemnikih ritonavirja, se lahko sčasoma zmanjša, ko se pojavi indukcija (glejte poglavje 4.4).
Recommendations regarding use of ritonavir dosed as a pharmacokinetic enhancer with rifabutin are noted in section
Priporočila za uporabo ritonavirja, odmerjanega kot farmakokinetičnega stopnjevalca z rifabutinom, so navedena v poglavju 4.5.
Specific recommendations for use of ritonavir as a pharmacokinetic enhancer in patients with hepatic impairment are dependent on the protease inhibitor with which it is co-administered.
Specifična priporočila za uporabo ritonavirja kot farmakokinetičnega stopnjevalca pri bolnikih z okvaro jeter so odvisna od zaviralca proteaz, s katerim je uporabljen.
Ritonavir steady-state pharmacokinetic parameters were evaluated in HIV infected children less than 2 years of age receiving doses ranging from 350 to 450 mg/m2 twice daily.
Farmakokinetični parametri ritonavirja v stanju dinamičnega ravnovesja so bili ocenjeni pri otrocih, okuženih s HIV, mlajših od 2 let, ki so dobivali odmerke od 350 do 450 mg/m2 dvakrat na dan.
Maximal inhibition of metabolism of the co-administered protease inhibitor is generally achieved with ritonavir doses of 100 mg daily to 200 mg twice daily, and is dependent on the co-administered protease inhibitor.
Največje zavrtje presnove sočasno uporabljenega zaviralca proteaz je praviloma mogoče doseči z odmerkom ritonavirja od 100 do 200 mg dvakrat na dan, odvisno pa je od sočasno uporabljenega zaviralca proteaz.
St John's wort is often used in herbal medicines that you can buy yourself.
Šentjanževka je pogosto sestavina zdravil rastlinskega izvora, ki jih lahko kupite brez recepta.
However, if the benefit outweighs the risk, co-administration of bedaquiline with ritonavir must be done with caution.
Vendar pa je, če je korist večja od tveganja, pri sočasni uporabi bedakilina z ritonavirjem potrebna previdnost.
Other medicines and Ritonavir Mylan
Druga zdravila in zdravilo Ritonavir Mylan
Saquinavir should only be given in combination with ritonavir.
Sakvinavir morate uporabljati zgolj v kombinaciji z ritonavirjem.
Some patients taking a number of antiretroviral medicines may develop this disease.
Ta bolezen se lahko pojavi pri nekaterih bolnikih, ki jemljejo številna protiretrovirusna zdravila.
Effect on Coadministered Medicinal Products AUC
Vpliv na AUC sočasno uporabljenega zdravila
In a clinical study investigating the interaction of rifampicin 600 mg once daily and saquinavir 1,000 mg with ritonavir 100 mg twice daily in healthy volunteers, severe hepatocellular toxicity with transaminase elevations up to > 20-fold the upper limit of normal after 1 to 5 days of co-administration was noted.
V klinični študiji, s katero so pri zdravih prostovoljcih raziskali medsebojno delovanje 600 mg rifampicina enkrat na dan ter 1000 mg sakvinavirja s 100 mg ritonavirja dvakrat na dan, so po 1 do 5 dneh sočasne uporabe zabeležili hude toksične učinke na jetrne celice z zvišanjem transaminaz do > 20-kratno zgornjo mejo normalnih vrednosti.
In contrast to long-term administration of ritonavir, there was no significant interaction with bupropion after short-term administration of low doses of ritonavir (200 mg twice daily for 2 days), suggesting reductions in bupropion concentrations may have onset several days after initiation of ritonavir co-administration.
V nasprotju z dolgotrajno uporabo ritonavirja po kratkotrajni uporabi majhnih odmerkov ritonavirja (200 mg dvakrat na dan, 2 dni) ni bilo pomembnega medsebojnega delovanja z bupropionom, kar kaže, da se lahko znižanje koncentracije bupropiona pojavi več dni po začetku sočasne uporabe z ritonavirjem.
The use of pethidine and ritonavir is contraindicated due to the increased concentrations of the metabolite, norpethidine, which has both analgesic and CNS stimulant activity.
Uporaba petidina in ritonavirja je kontraindicirana zaradi zvišane koncentracije presnovka norpetidina, ki deluje analgetično in stimulira osrednje živčevje.
Ritonavir is principally metabolised and eliminated by the liver.
Ritonavir se pretežno presnavlja v jetrih in izloča skoznje.
Higher doses of ritonavir have been shown to be associated with an increased incidence of adverse reactions.
Ugotovljeno je, da večje odmerke ritonavirja spremlja večja pogostnost neželenih učinkov.
However, clinical trials revealed no evidence of medicinal product-induced ocular changes in humans.
Klinična preskušanja pri ljudeh niso odkrile z zdravilom izzvanih sprememb na očeh.
Also tell your doctor if you experience joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty moving, as this may be a sign of osteonecrosis.
Prav tako morate zdravniku povedati, če se vam pojavijo togost sklepov, bolečine (zlasti v kolku, kolenu ali rami) in težave pri gibanju: to so lahko znaki osteonekroze.
Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and strong inhibitors of CYP3A like ritonavir (see sections 4.3 and 4.5).
Življensko ogrožujoče interakcije zdravil in tiste s smrtnim izidom so bile poročane pri bolnikih zdravljenih s kolhicinom in močnimi zaviralci CYP3A kot je ritonavir (glejte poglavji 4.3 in 4.5).
In vitro and in vivo studies have demonstrated that ritonavir is a potent inhibitor of CYP3A- and CYP2D6- mediated biotransformations.
Študije in vitro in in vivo kažejo, da ritonavir močno zavira biotransformacijo s CYP3A in CYP2D6.
The protein binding of ritonavir in human plasma is approximately 98 - 99% and is constant over the concentration range of 1.0 - 100 μg/ml.
Navidezni volumen porazdelitve (VB/F) ritonavirja je po enem samem 600 mg odmerku približno 2040 l. Vezava ritonavirja na beljakovine v človeški plazmi je približno 98-99 % in je v koncentracijskem območju od 1,0 do 100 g/ml stalna.
Since ritonavir is extensively metabolised by the liver and is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the medicine.
Ker se ritonavir izdatno presnavlja v jetrih in je zelo vezan na beljakovine, ni verjetno, da bi dializa pomembno odstranila zdravilo.
What Ritonavir Mylan looks like and contents of the pack Ritonavir Mylan film-coated tablets are yellow, capsule shaped and marked with ‘M163' on one side and plain on the other.
Filmsko obložene tablete Ritonavir Mylan so rumene tablete v obliki kapsule in imajo na eni strani oznako »M163«, na drugi strani pa nimajo oznake.
When used in combination with delavirdine, dose reduction of ritonavir may be considered.
Če je ritonavir uporabljen v kombinaciji z delavirdinom, pride v poštev zmanjšanje odmerka ritonavirja.
Co-administration of voriconazole and ritonavir dosed as a pharmacokinetic enhancer should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.
Sočasni uporabi vorikonazola in ritonavirja, odmerjanega kot farmakokinetični stopnjevalec, se je treba izogibati, razen če pretehtanje koristi in tveganj za bolnika upravičuje uporabo vorikonazola.
Concomitant use of ritonavir (500 mg twice daily) dosed as an antiretroviral agent and rifabutin due to an increase of rifabutin serum concentrations and risk of adverse reactions including uveitis (see section
Sočasna uporaba ritonavirja (500 mg dvakrat na dan), odmerjanega kot protiretrovirusno zdravilo, in rifabutina zaradi zvišanja koncentracije rifabutina v serumu in tveganja za neželene učinke, vključno z uveitisom (glejte poglavje .4).
Based on data for other CYP3A4 inhibitors, plasma concentrations of midazolam are expected to be significantly higher when midazolam is given orally.
Na podlagi podatkov o drugih zaviralcih CYP3A4 pa je mogoče pričakovati, da bodo plazemske koncentracije midazolama značilno višje po peroralni uporabi.
Increased plasma concentrations of alfuzosin which may lead to severe hypotension (see section 4.5).
Zvišana koncentracija alfuzosina v plazmi, kar lahko vodi v resno hipotenzijo (glejte poglavje 4.5)
Developmental toxicity in rabbits (embryolethality, decreased litter size and decreased foetal weights) occurred at a maternally toxic dosage.
Toksični učinki na razvoj pri kuncih (embrioletalnost, manjša velikost legla in zmanjšana fetalna masa) so se pojavili pri odmerkih, toksičnih za samico-mater.
400 q8 h
400 na 8 ur
500 q12 h ↓ 20%/↑ 20% ↔ Dose alteration of sulfamethoxazole/trimethoprim during concomitant ritonavir therapy should not be necessary.
500 na 12 ur ↓ 20 % / ↑ 20 % ↔ Med sočasnim zdravljenjem z ritonavirjem odmerka kombinacije sulfametoksazol/trimetoprim praviloma ni treba spreminjati.
Talk to your doctor before you take any cholesterol-reducing medicines with ritonavir (see also ‘Do not take Ritonavir Mylan' above).
Preden sočasno z ritonavirjem vzamete katerokoli zdravilo za zniževanje holesterola, se posvetujte z zdravnikom (glejte tudi Ne jemljite zdravila Ritonavir Mylan, zgoraj).
Ritonavir may induce the glucuronidation of zidovudine, resulting in slightly decreased levels of zidovudine.
Ritonavir lahko inducira glukuronidacijo zidovudina in koncentracija zidovudina se zato lahko rahlo zviša.
Your doctor will advise you on the dosage to be taken.
Zdravnik vam bo povedal, kolikšen je potrebni odmerek.
Adjustment to the dose of buprenorphine or ritonavir may therefore not be necessary when the two are dosed together.
Prilagoditev odmerkov buprenorfina ali ritonavirja v primeru njune skupne uporabe zato najbrž ni potrebna.
Ritonavir Mylan film-coated tablets should be swallowed whole and not chewed, broken or crushed.
Filmsko obložene tablete Ritonavir Mylan je treba pogoltniti cele in se jih ne sme žvečiti, prelomiti ali zdrobiti.
Saquinavir/ritonavir should not be given together with rifampicin, due to the risk of severe hepatotoxicity (presenting as increased hepatic transaminases) if the three medicines are given together (see section 4.5).
Sakvinavirja/ritonavirja ne smete dajati hkrati z rifampicinom: med sočasno uporabo teh treh zdravil namreč obstaja tveganje za hude hepatotoksične učinke (ki se pokažejo z zvišanjem jetrnih transaminaz) (glejte poglavje 4.5).
Co-administration of ibrutinib and ritonavir should be avoided.
Sočasni uporabi ibrutiniba in ritonavirja se je treba izogniti.
No medicinal product interaction study has been performed for the co-administration of ritonavir with benzodiazepines.
Študij medsebojnega delovanja glede sočasne uporabe ritonavirja in benzodiazepinov ni bilo izvedenih.
Feeling sick (nausea), vomiting or have stomach pain, because these may be signs of inflammation of the pancreas (pancreatitis).
občutek siljenja na bruhanje (navzea), bruhanje ali bolečine v zgornjem delu trebuha, kajti to so lahko znaki vnetja trebušne slinavke (pankreatitisa).
HMG co-A reductase inhibitors Atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin
Atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin
Dose of Coadministered Medicinal Products (mg)
Odmerek sočasno uporabljenega zdravila (mg)